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Most globally popular drugs are plant neurotoxins or their close chemical analogs. These
compounds evolved to deter, not reward or reinforce, consumption. Moreover, they reliably
activate virtually all toxin defense mechanisms, and are thus correctly identified by human
neurophysiology as toxins. Acute drug toxicity must therefore play a more central role in
drug use theory. We accordingly challenge the popular idea that the rewarding and rein-
forcing properties of drugs “hijack” the brain, and propose instead that the brain evolved to
carefully regulate neurotoxin consumption to minimize fitness costs and maximize fitness
benefits. This perspective provides a compelling explanation for the dramatic changes in
substance use that occur during the transition from childhood to adulthood, and for perva-
sive sex differences in substance use: because nicotine and many other plant neurotoxins
are teratogenic, children, and to a lesser extent women of childbearing age, evolved to
avoid ingesting them. However, during the course of human evolution many adolescents
and adults reaped net benefits from regulated intake of plant neurotoxins.
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The mesolimbic dopamine system (MDS)1 plays a key, though
still not fully understood, role in the ability of laboratory ani-
mals to learn an association between a stimulus, such as a tone,
and a natural reward, such as sugar water, and to approach and
consume the reward (1–6). Drugs of abuse have neurobiological
and behavioral effects that closely resemble the effects of sugar
and other natural rewards, activating the MDS and producing
approach and consummatory behavior, positive feelings, and the
learning of cues that predict drug availability. Drugs are rewards
(7). Moreover, drugs and sugar are chemically similar: both are
small organic molecules that act as ligands for various receptors.
In fact, fermentation converts 1 glucose molecule into 2 ethanol
molecules (and 2 CO2 molecules), and ethanol contains more
calories per gram than glucose (7 vs. 4), underscoring the compa-
rability of a natural reward and a drug. On what basis, then, do
neurobiologists classify drug reward as abnormal and food reward
as normal?
1. THE HIJACK HYPOTHESIS
Numerous, highly cited articles that review the neurobiology
of drug use employ similar metaphors to distinguish nat-
ural rewards from drugs: natural rewards “activate” the MDS,
whereas drugs “hijack,”“usurp,”“co-opt,” or artificially stimulate it
1The MDS comprises dopamine (DA) neurons located in the midbrain structures
of the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc) that
project to the nucleus accumbens (NAc) and dorsal striatum.
[e.g., Ref. (7–15)]. Kelley and Berridge [(9), p. 3306], for instance,
open their review with:
Addictive drugs act on brain reward systems, although the
brain evolved to respond not to drugs but to natural rewards,
such as food and sex. Appropriate responses to natural
rewards were evolutionarily important for survival, repro-
duction, and fitness. In a quirk of evolutionary fate, humans
discovered how to stimulate this system artificially with drugs.
In another review, Hyman [(11), p. 1414] leads into a section titled
“A Hijacking of Neural Systems Related to the Pursuit of Rewards”
with:
[A]ddiction represents a pathological usurpation of the
neural mechanisms of learning and memory that under nor-
mal circumstances serve to shape survival behaviors related
to the pursuit of rewards and the cues that predict them.
On the evolutionary novelty of drug dependence, Wise [(8), p. 27]
is perhaps most explicit:
Addiction is quite a recent phenomenon, largely depen-
dent upon the controlled use of fire (smoking), hypodermic
syringes (intravenous injection), and the cork and bottle
(storage and transportation of alcohol). Thus, while brain
dopamine is activated by most drugs of abuse, the drugs have
undergone mostly human selection for their ability to activate
the system; the system has not undergone natural selection
because of its sensitivity to the drugs.
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We refer to these arguments as the “hijack hypothesis.” We rec-
ognize, on the one hand, that this is a metaphor invoked by
drug researchers to help explain the effects of drugs of abuse
on the brain. On the other hand, its frequent appearance in
prominent review articles suggests that drug abuse researchers
consider it to provide a fundamental distinction between addictive
substances and food. This distinction is based on the follow-
ing Darwinian propositions: the MDS evolved to enhance access
to some substances, like sugar, that increased fitness2; these are
termed “natural rewards.” It did not evolve to respond to known
drugs of abuse because these did not increase fitness and because
repeated consumption of such substances is an evolutionary
novelty3.
Unfortunately, most drug researchers do not seem to regard the
hijack hypothesis as a hypothesis. Instead, it is treated as an axiom
or truism that requires little supporting evidence. The most impor-
tant point of our commentary is that the evolutionary premises of
the hijack hypothesis are empirically testable.
Previous work has criticized the hijack hypothesis on a number
of grounds (see, for instance, articles in this special issue). In par-
ticular, although laboratory studies demonstrate that animals will
self-administrate most drugs of abuse, these studies rarely provide
the animals with alternative rewarding choices. In studies that do
provide a rewarding alternative, such as sweetened water or social
interactions (as in the famous Rat Park experiment), most animals
choose the alternative, not the drug, undermining the claim that
drugs hijack decision-making machinery (19).
Here we briefly summarize our previous critique of the
hijack hypothesis’ evolutionary premises (20–22). It is impor-
tant to emphasize that we only critique these premises, not the
evidence on the neurobiological mechanisms involved in drug
use nor the various interpretations of dopamine function. We
then sketch an evolutionary alternative to the hijack hypothesis:
the neurotoxin regulation hypothesis. We conclude by consider-
ing age and sex differences in substance use in light of both
hypotheses.
A caveat: neurobiological theory of drug use usually contrasts
initial seeking and use with longer-term phenomena such as
drug tolerance and addiction. We focus on initial drug seeking
and use for several reasons: there are a small number of simple
information-processing models of initial drug seeking and use,
often dubbed“reward models.”Current research on drug tolerance
and addiction, in contrast, lacks a similarly concise, well-accepted
conceptual framework [for a review of various theories of addic-
tion, see Ref. (23)]. Moreover, tolerance and addiction are generally
attributed, in part, to complex changes in neurobiology induced by
long-term drug exposure. It is difficult to evaluate which changes
are due to the effects of drugs and which to the nervous system’s
attempt to adapt to drug exposure, complicating an evolutionary
analysis.
2By “fitness” we mean biological fitness – the average contribution to the gene pool
of the next generation. For a review of fitness concepts, see Ref. (16).
3Some have recently argued that sugar is itself a potential substance of abuse [e.g.,
Ref. (17)], which again requires an appeal to evolutionary novelty, in this case the
novelty of access to relatively unconstrained quantities of sugar [e.g., Ref. (18)].
2. MOST DRUGS ARE PLANT DEFENSIVE CHEMICALS OR
CLOSE CHEMICAL ANALOGS
Terrestrial plants and animals appeared ∼400 million years ago.
Animals evolved to exploit plant tissues and energy stores, and
in response, plants evolved numerous defenses, including toxins.
These toxins appear in high concentrations in some organs, like
leaves, that are critical for plant growth, survival, and reproduc-
tion, and in low concentration in other organs, like ripe fruits, that
evolved to be consumed by herbivores to aid seed dispersal, which
is beneficial for the plant.
Plant drugs, such as caffeine, nicotine, cocaine, and THC,
belong to a subcategory of toxins that evolved to interfere with
neuronal signaling in herbivores. Depending on the toxin, this
includes interference with: (1) neurotransmitter synthesis, storage,
release, binding, and re-uptake, (2) receptor activation and func-
tion, and (3) key enzymes involved in signal transduction (24).
Plant drugs therefore did evolve to “hijack” herbivore nervous sys-
tems, but for an effect that is precisely the opposite of the hijack
hypothesis: to deter, not reward, or reinforce, plant consumption.
(We prefer describing these effects as “interference” rather than
“hijacking.”)
Plant toxins have had a profound influence on the evolution of
herbivore neurophysiology, resulting in: (1) numerous chemosen-
sors including bitter taste receptors, (2) detoxification mechanisms
including cytochrome P450 and other enzymes, (3) cellular mem-
brane carrier proteins for toxin transport, including ATP-binding
cassette proteins, and (4) aversive learning mechanisms that per-
mit selective feeding on less toxic tissues (25, 26). Many herbivore
defensive proteins are expressed in the blood-brain barrier and
the brain itself, including in humans (27–30), indicating the fit-
ness advantages of protecting the CNS specifically from plant
neurotoxins and other xenobiotics.
From an herbivore’s perspective, then, the value of a plant
substance usually comprises the benefits of useable macronutri-
ents (carbohydrates, fats, and proteins) minus the costs of toxin
exposure.
2.1. BENEFITS OF TOXIN CONSUMPTION IN NON-HUMAN ANIMALS
Although exposure to plant toxins is ordinarily costly for her-
bivores, herbivores have also evolved to exploit plant toxins for
herbivore benefit, which often involves prophylactic or therapeu-
tic effects against pathogens, i.e., self-medication (also known as
pharmacophagy or zoopharmacognosy) (31–43). Originally pro-
posed as a primate behavior, evidence for self-medication is now
available from diverse non-human species, including fruit flies
(40, 41), ants (44), moths (39), butterflies (45, 46), honeybees (47,
48), birds (42), sheep (49), goats (50), and Neanderthals (51). In
many of these studies (but not all), animals increase toxin intake in
response to infection. More generally, there is growing recognition
that animal defenses against pathogens include not only immune
system responses, but also behavioral responses, termed behavioral
immunity or non-immunological defense, of which self-medication
is one example (52, 53).
In summary, animals have been exposed to plant toxins, likely
including those affecting the CNS, for hundreds of millions of
years. Animals can also extract benefits from such exposure. Thus,
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the evolutionary premises of the hijack hypothesis – that, for
humans, drug exposure is evolutionarily novel and has no fit-
ness benefits – are questionable and cannot be accepted without
considerable further evidence.
2.2. NICOTINE AS A MODEL DRUG
In what follows we will often rely on studies of tobacco and nico-
tine for the following reasons: first, nicotine is globally popular
and highly addictive. Second, it is a plant drug, and therefore
belongs to the category of substances that most animals were reg-
ularly exposed to during their evolution. Third, it is not out of the
question that humans have chewed or smoked various psychoac-
tive plants for hundreds of thousands of years, just as tobacco is
consumed today. Fourth, the role of nicotine as a plant defensive
chemical is well-documented (54, 55). And fifth, there is extensive
research on nicotine.
We will also draw on the extensive research on pharmaceu-
ticals and pesticides because often these are derived from plant
toxins (e.g., nicotine, which has therapeutic applications and is
also widely used as a pesticide), chemically resemble plant tox-
ins, or have neurophysiological effects analogous to plant toxins.
Data on them will therefore help us illuminate neurophysiological
responses to plant toxins.
2.3. NICOTINE TOXICITY
Although neurobiology emphasizes the rewarding properties of
nicotine, nicotine is an extremely potent neurotoxin. In humans,
the lethal dose of nicotine is∼10 mg in children and 30–60 mg in
adults, a toxicity comparable to hydrogen cyanide (56). Death can
occur within 5 min after consumption of concentrated nicotine
insecticides (57). A single cigarette typically contains 10–20 mg
of nicotine, but much of it is burned; smokers thus absorb 0.5–
2 mg per cigarette, and users of smokeless tobacco about twice this
much (58).
Despite the evolutionary novelty of human exposure to
nicotine4, nicotine activates most known human toxin defense
mechanisms, such as bitter taste receptors in the mouth and
gut (62), bitter taste pathways in the peripheral nervous sys-
tem (63), xenobiotic-sensing nuclear receptors (64), xenobiotic-
metabolizing enzymes (58), aversion circuitry in the CNS (65),
and conditioned taste avoidance (66).
In individuals not habituated to nicotine, 0.6 mg (one “light”
cigarette) can induce sweating, nausea, dizziness, coldness of
hands, palpitations, headache, and upset stomach (67); 4–8 mg
often produces serious symptoms, including burning sensations
in the mouth and throat, profuse salivation, vomiting, abdominal
pain, and diarrhea (57).
Human neurophysiology thus correctly identifies nicotine as a
dangerous toxin and generates appropriate avoidance and expul-
sion responses. Because nicotine is not thought to be directly
4Whereas humans evolved in the Old World, all but one of the 60–70 tobacco species
(genus Nicotiana) are native to the Americas or Oceania (one species is native to
Africa). N. tabacum, the species of primary commercial importance, was domesti-
cated by Native Americans within the last several thousand years, and spread to the
Old World in the last few hundred years (59–61). Although nicotine is present in a
number of plants native to the Old World, it is currently difficult to make the case
that human ancestors were regularly exposed to nicotine.
responsible for the chronic diseases caused by smoking (68) [cf.
Ref. (69)], its toxicity plays little role in research on tobacco use.
More generally, although drug researchers have long recognized
that drugs are toxins and have aversive effects, and that drug toxi-
city and aversiveness is at odds with drug reward [for reviews, see
Ref. (70–72)], this insight has had little influence on drug use the-
ory (72). In the framework we develop here, however, drug toxicity
plays a central role.
3. THE NEUROTOXIN REGULATION HYPOTHESIS
Herbivores and omnivores, including humans, obtain substantial
macronutrients from plants. Plant choice in non-human animals
is heavily influenced by toxin concentration, which appears to be
assessed by chemosensors in, e.g., the mouth and gut, followed by
conditioned learning and social learning (e.g., observing mother’s
plant choices) (73, 74). Complete avoidance of plant toxins is not
an option, however. Mammalian herbivores cap the daily amount
of ingested plant toxins by modulating intake to accommodate
changes in the dietary concentration of toxins. They are able to do
this even for toxins that are, for them, evolutionarily novel (75). It
appears that herbivores regulate the dose of plant toxins to keep
blood concentrations below a critical level [Ref. (76), and refer-
ences therein]. At the same time, because plant toxins can provide
fitness benefits, regulatory mechanisms should not, and could not,
completely eliminate exposure to plant toxins but instead balance
dose-dependent costs vs. benefits, and adjust intake accordingly
[Ref. (74, 77, 78), and references therein].
In our view, drug toxicity poses two major challenges to any the-
ory of drug use. First, why do humans ignore cues of toxicity, like
bitter taste and nausea, to regularly and deliberately consume non-
trivial doses of potentially lethal substances that provide essentially
no macronutrients? Second, given that humans do consume such
substances, how and why does human neurophysiology success-
fully meter their intake? The hijack hypothesis seems to imply
that drug consumption is regulated, at least in part, by the same
mechanism that regulates consumption of sugar and other foods.
Humans consume tens-to-hundreds of grams of sugar and other
carbohydrates per meal. Typical doses of recreational drugs, on
the other hand, are tiny – on the order of milligrams or tens of
milligrams – and are not far below a lethal dose (79); yet over-
doses and death are relatively rare5. We find it surprising that the
inadvertent triggering of a mechanism that evolved to reward and
reinforce intake of large quantities of macronutrients results in the
precisely metered intake of minute quantities of neurotoxins.
We therefore propose that the brain might not accidentally
reward or reinforce consumption of nicotine and other addictive
drugs, as the hijack model proposes, nor generate purely aversive
reactions, as drug toxicity would suggest, but instead has evolved
specialized mechanisms to precisely regulate drug consumption to
minimize costs and maximize benefits [Ref. (22) cf. Ref. (81)].
5Drugs that are injected, and thus bypass peripheral chemosensors, are a partial
exception. In the US in 2008, for example, there were about 1.9 million cocaine
users and 5100 cocaine-related lethal poisonings, for an annual rate of 0.27%, which
includes users who injected cocaine (CDC, NIH). A study of lethal cocaine-related
deaths in Australia found that 86% involved cocaine injection and 81% also involved
other drugs, mostly opioids, alcohol, and benzodiazepines (80). Thus, death from
non-injected cocaine is rare.
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A neurotoxin regulation mechanism would only evolve if,
in fact, there were fitness benefits to neurotoxin consumption.
We have proposed numerous potential benefits of psychoactive
drug use, including enhancement of attention, memory and other
aspects of cognition and physiology, and redressing nutrient defi-
ciencies and neurotransmitter dysregulation (20–22). Later, we
sketch another possible benefit involving attraction of mates and
other social partners.
Our principal hypothesis, however, has been that human con-
sumption of plant neurotoxins helps prevent or treat infection
by parasites with nervous systems, i.e., macroparasites such as
helminths [see also Ref. (82)], similar to the self-medication
observed in many other animals species. Helminth parasites have
been an important selection pressure in vertebrate and mam-
malian evolution, and in human evolution specifically (83, 84).
Over one third of the global population remains infected by
them (85). Helminths are often able to evade the immune system
(86, 87), so chemotherapeutic intervention is frequently necessary
to clear infections. There is increasing evidence that some non-
human animals consume plant toxins specifically to prevent or
treat helminth infections (49, 50) [but see Ref. (88)].
Intriguingly, three of the world’s most popular psychoactive
drugs – nicotine, arecoline (from betel-nut) and THC – are effec-
tive against helminths and other macroparasites; to this day some
farmers and veterinarians deworm animals with nicotine or areco-
line (89–98). Some helminth species have a larval stage that
migrates through the lung (84), which perhaps was a selection
pressure specifically to smoke neurotoxic plants6.
An evolved mechanism to self-medicate with psychoactive
substances should up-regulate consumption and down-regulate
elimination of such substances in response to infection and/or
infection risk. There are intriguing hints that infection risk and
immune system signals do just that7. The “proinflammatory
hypothesis of drug abuse” has emerged from growing evidence of
immune involvement in drug reinforcement (102–104). Opioids,
for instance, perhaps acting as xenobiotic-associated molecular
patterns, activate toll-like receptor 4 (TLR4) signaling (impor-
tant for pathogen recognition and immune activation), which
surprisingly reinforces opium consumption via the mesolimbic
dopamine reward pathway (105). Especially intriguing is direct
evidence that the immune system modulates intake of the psy-
choactive drug ethanol (106, 107). One genome-wide association
study found that smoking behavior might be regulated by IL-
15, which is involved in immune signaling (108). Such results
indicate an intimate relationship between psychoactive drug use
and immunity, and, importantly, that central immune signals can
modulate drug consumption.
Down-regulation of drug metabolism during infections would
increase blood concentrations of potentially therapeutic agents.
Infection and inflammation are indeed associated with a
broad down-regulation of xenobiotic-metabolizing enzymes and
transporters in humans and laboratory animals (albeit with
complications for CYP2A6, which metabolizes nicotine), which
6Contrary to Wise (8), there is archeological evidence for controlled use of fire c.
790 KYA – 1 MYA (99, 100), long before the evolution of Homo sapiens.
7The prevailing view is that the causal arrow usually points in the opposite direction,
i.e., that drug abuse increases infection risk by impairing immunity (101).
often results in a pronounced increase in plasma concentrations
of various drugs. This well-documented but poorly understood
phenomenon (109) could also be evidence for a self-medication
mechanism.
Although it might not be intuitive to reconceptualize recre-
ational drug use as a means to prevent or treat macroparasite
infections (chemoprophylaxis and chemotherapy, respectively),
we point out that prior to the discovery of sodium’s role in
body fluid homeostasis, our evolved appetite for salt was utterly
mysterious.
There is considerable evidence that nicotine intake is tightly
controlled. If nicotine were purely rewarding or reinforcing, then
lethal nicotine overdoses among adult tobacco users should be
common. Instead, they are extremely rare (79). Behaviorally, cig-
arette smokers appear to titrate nicotine, altering their smoking
behavior in response to changes in nicotine content so as to main-
tain a relatively constant blood concentration of nicotine (110).
Both facts support the existence of a regulatory mechanism.
The putative regulatory mechanism might involve the MDS,
which seems to play a central role in weighing the costs of behav-
iors, not just benefits. A subpopulation of dopamine neurons in
the MDS is excited by aversive stimuli and cues that predict aver-
sive stimuli (111–113). There is even one report that bitter taste
receptors are expressed in the rat MDS (30). Given the anatomical
proximity of the targets of aversion- and reward-related dopamine,
their interaction could be the neurophysiological basis for weigh-
ing costs against benefits (2, 114). Interestingly, the MDS appears
to be involved in the neurophysiological system that evolved to reg-
ulate intake of small quantities of sodium (115, 116). We envision
the hypothesized neurotoxin regulation mechanism to be some-
what analogous to the salt appetite regulation mechanism in that
it would employ numerous peripheral and central chemosensors
and feedback circuits to precisely meter intake of milligrams of
environmental chemicals.
Unlike the sodium regulation mechanism, the putative neu-
rotoxin regulation mechanism must titrate a diverse range of
compounds, many of which would be evolutionary novel for the
organism: plants are constantly evolving new chemical defenses,
and both plants and animals migrate. Currently, it is not pos-
sible to fully explain how a limited number of toxin defense
proteins, which would be the foundation of a regulatory mech-
anism, selectively bind to a large range of chemically diverse
toxins. Understanding the relationship between the physiochem-
ical properties of a toxin molecule and its biological activity – its
structure-activity relationship – is a dynamic and challenging area
of research [e.g., Ref. (117)]. Part of the answer is that most tox-
ins belong to one of a smaller group of chemical families, such as
fatty acids, peptides, amino acids, amines, amides, azacycloalkanes,
N-heterocyclic compounds, ureas, thioureas, carbamides, esters,
lactones, carbonyl compounds, phenols, crown ethers, terpenoids,
secoiridoids, alkaloids, glycosides, flavonoids, and steroids (118).
Molecules belonging to the same family tend to share chemical
properties8. Thus, binding regions of defensive proteins might be
specific for classes of compounds.
8But it is not uncommon for small chemical changes to result in large changes in
bioactivity.
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In addition, chemically diverse toxins can interfere with the
same signaling pathway (e.g., nicotine, a small organic molecule,
and botulinum toxin, a protein, both interfere with cholinergic
signaling). We speculate that a neurotoxin regulation mechanism
might be able to detect interference with neural signaling pathways,
and modulate intake accordingly. We also speculate that individ-
ual learning plays an important role in the neurotoxin regulation
mechanism. Given exposure to a novel neurotoxin with unknown
costs and benefits, a user should first ingest minute quantities,
gradually increasing intake to optimize benefits vs. costs, which
resembles patterns exhibited by laboratory animals and humans
with extended access to drugs (119).
4. AGE DIFFERENCES IN DRUG USE: A DEVELOPMENTAL
SWITCH?
There are dramatic changes in substance use across the lifes-
pan, which provide an opportunity to empirically test the hijack
hypothesis against the neurotoxin regulation hypotheses. Do these
changes reflect changes in vulnerability to hijacking? Or do they
reflect age-related changes in the costs and benefits of exposure to
plant toxins that should up- or down-regulate ingestion?
Users of popular psychoactive substances report virtually no
use prior to the age of 10 (with the partial exception of alcohol).
Starting about the age of 12 there is a rapid increase in substance
use, so that almost everyone who will ever use a substance has
done so by age 20 (Figure 1). The pattern suggests the existence of
a developmental “switch.”
The complete lack of child substance use seen in the self-report
data in Figure 1 are corroborated by serum cotinine values from
a nationally representative US sample (Figure 2). Cotinine, the
primary metabolite of nicotine, is a reliable and widely used bio-
marker of exposure to tobacco, via either tobacco consumption
or environmental tobacco smoke (ETS) (121). The cotinine con-
centration of a smoker is usually ∼100 ng/ml, whereas that of
a non-smoking child living with smokers is usually <10 ng/ml
(121, 122)9.
Figure 2 depicts 12 years of data (1999–2010) that include 5932
children ages 3–10 (123), 1111 of whom (19%) lived with a smoker,
and thus presumably had easier access to tobacco. Among all
children, 94.5% of the cotinine concentrations are ≤3 ng/ml and
99.4% are ≤10 ng/ml. These values are within the range of values
seen in non-smokers exposed to ETS, e.g., from a smoking parent
or other caregiver10. Only 33 children (0.6%) had cotinine values
>10 ng/ml, and 6 (0.1%) had values >20 ng/ml, with the maxi-
mum value (32.4 ng/ml) occurring in a 4-year old. These values
9Distinguishing smokers from non-smokers exposed to ETS based on cotinine val-
ues alone is complicated by the many sources of variability, such as amount of
nicotine exposure, time between last exposure and sample collection, and differ-
ences in nicotine and cotinine metabolism due to, e.g., common polymorphisms
in the enzymes that metabolize them (primarily CYP2A6). A smoker who hadn’t
smoked recently and a non-smoker exposed to heavy ETS might both have a cotinine
concentration of 10 ng/ml, for instance. Estimates of the optimal serum cotinine
concentration for distinguishing tobacco users from non-users exposed to ETS range
from 3 to 15 ng/ml (121).
10In children living with smokers, the highest cotinine values in occurred in the
younger children, suggesting physical proximity to a primary caregiver who is
a smoker, or greater absorption and/or slower clearance of nicotine in younger
children.
overlap with the values of smokers who haven’t smoked recently,
but are still within the range of values that could result from heavy
ETS, such as traveling in a car with a heavy smoker (121)11.
What explains the dramatic lack of child substance use, and the
equally dramatic transition to substance use during adolescence?
4.1. THE HIJACK MODEL OF CHILDREN’S LOW-TO-NON-EXISTENT
SUBSTANCE USE
The hijack hypothesis predicts that anyone with a functional MDS,
that is, anyone for whom sugar is rewarding or reinforcing, will be
susceptible to tobacco and other drugs. The everyday experience
that children enjoy sweets, and thus have a functional reward sys-
tem, is confirmed by studies of: (1) diet across the lifespan that
show that a substantial fraction of the daily energy intake for
US children and adolescents comes from sugar added to bever-
ages and foods (125, 126), and (2) reinforcement learning that
find that although children and older adults do show “deficits”
in some aspects of reward processing relative to younger adults,
reward-based learning mechanisms are quite functional in chil-
dren (127). The hijack hypothesis therefore predicts that, all else
equal, children would consume drugs of abuse at rates similar to
adolescents and adults, contrary to the evidence in Figure 1. On its
own, the hijack hypothesis cannot explain the dramatic changes in
substance use across the lifespan. Drug use researchers therefore
typically invoke additional explanations.
An influential hypothesis attributes the onset of drug use to a
transient “imbalance” between the MDS and the prefrontal cor-
tex (PFC) that emerges in adolescence. The PFC is believed to be
responsible for executive control functions such as self-regulation,
abstract reasoning, deliberation, response inhibition, and planning
ahead (128–130). According to the hypothesis, these functions
manage or curb the rewarding and reinforcing signals from the
MDS, including those generated by drug use. The key insight of this
hypothesis is that the MDS and PFC have different developmental
trajectories: the MDS is largely mature by adolescence but the PFC
is still developing into early adulthood. It is thought that the still-
maturing PFC cannot adequately control the heightened reward
responsiveness stemming from the mature MDS, thus explaining
why adolescents engage in risky behaviors, such as unprotected sex
and drug use [e.g., Ref. (129–131), and references therein].
How does the imbalance model explain the lack of child drug
use? To our knowledge, the proponents of this model have not
explicitly discussed child drug use. However, the clear implication
would seem to be that in children, prefrontal cortex circuits, and
the MDS, though still developing, are“balanced,”so the PFC is able
to successfully manage the MDS, explaining why children typically
do not engage in risky behavior. Specifically, child enjoyment of
drugs would be successfully overridden by the executive control
circuits of the PFC. This requires that children know that drug use
is risky. We guess that proponents of this model would argue that
parents and others teach children about the dangers of drugs. In
addition, parents and society impose restrictions on child access
to drugs.
11A study of 42 non-smoking bar staff, for example, found a mean cotinine value of
9.28 ng/ml, with 3 individuals having values >20 ng/ml, and a maximum value of
31.3 ng/ml (124).
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FIGURE 1 | Cumulative distribution of self-reported age of first use of
(A) alcohol, (B) tobacco, (C) cannabis, and (D) cocaine in a large (N =85,052)
cross-national sample of users of these substances from the World Mental
Health Survey Initiative. These patterns suggest the existence of a
developmental “switch” that flips during adolescence. Figures from
Ref. (120).
Restricted access to tobacco could explain low-to-non-existent
child use. In the US, the sale of tobacco to minors is illegal in
all 50 states. Moreover, the US spends over $500 million annu-
ally on tobacco control measures (132), which include mass media
anti-tobacco campaigns; disseminating health warnings via, e.g.,
cigarette packages and advertising; enforcing bans on tobacco
marketing; monitoring tobacco use; enforcing some smoke-free
legislation; and providing some tobacco cessation health care
programs. Tobacco taxes also deter use.
If such warnings and social restrictions account for low child
substance use, then, according the hijack model, children should
readily consume plant drugs when they are absent. Caffeine, a
bitter-tasting plant toxin12, is a psychostimulant that strongly
12There are two hypotheses for the evolution of caffeine, which is found in sev-
eral plant species: herbivore defense, and allelopathy – inhibiting the germination of
competing plants (133). Caffeine in nectar might have evolved to enhance pollinator
memory (134).
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FIGURE 2 | Serum cotinine concentration vs. age in a sample of 18,382
children, adolescents, and young adults from the US National Health
and Nutrition Examination Survey 1999–2010. There is no unequivocal
evidence of tobacco consumption prior to age 11. (6 Cotinine values
>500 ng/ml were omitted for clarity, all from individuals >17 years old.) Data
from Ref. (123).
interacts with the central dopaminergic systems via antagonism
of endogenous adenosine (135). Caffeine is added to numerous
beverages marketed to children, which suggests that parents and
society are not overly concerned about child caffeine consump-
tion. In fact, the daily amount of caffeine consumed from soft
drinks is similar in US children, adolescents, and adults (136). It is
far from clear, however, that the rewarding properties of caffeine
motivate child consumption of soft drinks. Soft drinks contain
high levels of sugar and other sweeteners, and, compared to coffee,
about 1/3 the concentration of caffeine. The rewarding properties
of sugar and artificial sweeteners obviously play a major role in
child consumption of soft drinks; the role of caffeine is unclear.
Coffee consumption patterns should be informative because
coffee contains a rewarding psychoactive substance (caffeine),
does not necessarily contain sugar, and, unlike tobacco, is not
subject to national or global efforts to control its consumption.
Under the imbalance model, consumption of coffee should there-
fore be similar in children and adults. Yet coffee consumption
is extremely low in US children, with a transition to adult lev-
els occurring in adolescence and early adulthood (Figure 3),
resembling the age pattern of tobacco use. The similar age pat-
terns of tobacco and coffee consumption despite the profound
difference in social restrictions on child access to tobacco vs. cof-
fee, shows, at a minimum, that such restrictions play a smaller
role in child drug consumption patterns than is commonly
thought (we do not dispute their importance for adolescent and
adult drug use prevalence). As we argue next, low drug use
by children is probably better explained by child aversion to
drugs.
4.2. THE NEUROTOXIN REGULATION MODEL OF CHILDREN’S
LOW-TO-NON-EXISTENT SUBSTANCE USE
Because we take an evolutionary perspective, we consider the bio-
logical fitness consequences of plant toxin exposure to ancestral
FIGURE 3 | Daily caffeine intake from coffee per kilogram of body
weight in a sample of US caffeine consumers. Data from Ref. (136).
human children, who subsisted on wild foods. Virtually all wild
plant foods, including fruits, contain toxins (137). A wild fruit
contains substantial macronutrients, however, whose benefits can
offset the cost of its toxins. A dried leaf of a neurotoxic plant, on
the other hand, has virtually no macronutrients to offset the costs
of its toxins. Thus, under the neurotoxin regulation hypothesis,
consumption of the dried leaf would only occur when the benefits
of toxin exposure outweigh the costs. Our basic premise, which we
explain in detail next, is that during childhood the costs of toxin
exposure outweigh the benefits, so that drug use is very low, but
during adolescence the balance shifts, so that increased benefits
outweigh diminishing costs, leading to substantial drug use.
4.2.1. Age differences in the costs of neurotoxin exposure
We focus first on the fitness costs of exposure, and how these
change during development. Due to differences in body mass
alone, the cost of ingesting, e.g., 10 mg of nicotine, is much more
dangerous to a 5-year old than a 15-year old. In addition, children
have a considerably higher daily caloric requirement per kilogram
of body mass: 2 year olds (a typical age of weaning in natural fer-
tility populations) require about 80 kcal/kg/day, which decreases
by young adulthood to about 40–50 kcal/kg/day (138, 139). This
means that young children are eating almost twice as much food
per kilogram of body mass as adults. Because ancestral humans
relied on wild foods, higher caloric intake per unit mass implies
potentially greater exposure to plant toxins per unit mass (depend-
ing on the “quality” of the diet, e.g., the mix of plant and animal
foods).
This higher potential exposure has a number of implications.
First, toxin defense pathways have limited capacities and can
become saturated (140). Hence, consumption of a plant drug in
addition to toxin-rich plant foods could cause toxin levels to reach
dangerous levels. Second, toxin metabolism and elimination is
energetically expensive (141), reducing energy available for, e.g.,
growth and immunity.
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Disruption of development is perhaps the greatest cost of
plant toxin exposure for children, though, because it can perma-
nently impair functionality. Indeed, there is an entire discipline –
teratology – devoted to investigating the role of environmental
compounds in developmental disruption. Developmental toxicity
is often distinct from systemic toxicity. For instance, low doses
of some pesticides that cause little systemic toxicity nevertheless
disrupt neural development, whereas near lethal doses of other
pesticides have no discernible effect on neural development (142).
The thalidomide tragedy provides another example: thalidomide
was a sedative that was also effective against pregnancy sickness.
Due to its low acute toxicity and the absence of teratogenic effects
in rodents, it became quite popular in the 1960s until its severe
teratogenic effects in humans – deformed limbs and organ defects
in 20–30% of exposed infants – were recognized (143). The lack of
teratogenicity in rodents might be due, in part, to their ability to
rapidly metabolize and eliminate thalidomide, compared to much
slower elimination in humans (144). These examples demonstrate
that, for children, exposure to plant toxins can have costs above
and beyond systemic toxicity, and that toxin metabolism is a key
defense13.
Some popular plant drugs are indeed potent teratogens. Nico-
tine, for example, interferes with acetylcholine signaling, which
has a unique trophic role in brain development, modulating the
patterns of brain cell replication and differentiation, synaptic out-
growth, and architectural modeling. All phases of brain assembly,
from the early embryonic stage through adolescence, are pro-
foundly vulnerable to disruption by nicotine exposure (145, 146).
Even child exposure to environmental tobacco smoke (cotinine
concentrations of ∼1 vs. >100 ng/ml in tobacco users) is asso-
ciated with deficits in neurodevelopment, intelligence, attention,
and academic achievement (147, 148). Cholinergic signaling also
plays an important role in non-neuronal cells, including those of
the immune system, lungs, gut, and testes (149, 150), so nicotine
and other cholinergic toxins could disrupt their development and
function as well.
Consistent with these facts, there is considerable evidence for
heightened toxin defenses during childhood. The best defense is
to avoid ingesting toxic substances, and children reject many more
foods than adults. Not surprisingly, vegetables and fruits are the
most frequently rejected foods. There are two distinct, but closely
related, psychological factors related to rejection of foods prior to
ingestion: neophobia (rejection of novel foods), and “picky/fussy”
eating (rejection of many foods, regardless of their novelty).
Neophobic food rejection occurs primarily due to visual cues.
Foods that do not “look right” – green vegetables for exam-
ple, or foods that resemble known bitter foods – are rejected
without being placed in the mouth. Food neophobia is low at
weaning, increases sharply as a child becomes more mobile (so
parents would have less control over food choice), peaks between
2 and 6, and then decreases with age, becoming relatively sta-
ble in adulthood. Some studies show an inflection point at the
13Metabolism can also convert non toxic compounds into toxins (e.g., thalidomide
metabolites are biologically active), which probably illustrates the truism that no
defense mechanism is perfect.
onset of adolescence. The developmental trajectory of neopho-
bia is widely interpreted to reflect an evolved defense against
plant teratogens (151, 152). We see an important role for parental
warnings in child ingestive behavior. Children should be averse to
substances described by others as bitter or“bad.”Unlike the imbal-
ance model, however, parental warnings about drugs are taken as
cues of toxicity rather than an attempt to restrict access to desired
substances.
Foods that are placed in the mouth are rejected primarily based
on taste, especially bitter taste (though sometimes on texture)
(152). Taste is responsible for evaluating the nutritious content of
food and preventing the ingestion of toxic substances (see Box 1
for discussion of bitter taste physiology and genetics). Detection
thresholds for bitter compounds are extremely low, in some cases
as low as nano- or micro-molar concentrations (153), whereas
those for sucrose are about 1000× higher (154).
Children 7–8 years old have a higher density of taste buds on
the tip of the tongue than adults, and density is positively related
to taste sensitivity. This density decreases to the adult level by
about 9–10, with developmental changes complete by about age
11–12 (160). Children are indeed more sensitive to the bitter taste
of PROP than adults, and are up to twice as likely to be super-
tasters (161), with the transition to adult sensitivity seeming to
occur in adolescence [Ref. (162, 163), and references therein]. This
age dependence might be greatest in T2R38 heterozygotes (163).
(See Box 1). High bitter taste sensitivity leads to reduced con-
sumption of bitter vegetables (e.g., cabbage, broccoli, asparagus,
and spinach), especially in children (161).
All common recreational plant drugs, including nicotine, taste
bitter. Ethanol has both bitter and sweet taste components (164).
Thus, taste receptors properly recognize most popular psychoac-
tive drugs as toxic. Given children’s heightened neophobia, bitter
sensitivity, and pickiness, they probably find most psychoactive
drugs to be especially unpalatable14.
The second major toxin defense is neutralization and elimina-
tion of ingested toxic substances, often via metabolism in the liver.
As a percentage of body mass, liver volume is about 60% bigger
in young children than in adults (165). Child drug clearance rates
are very low at birth but reach adult levels by about 1 year, and
then surpass adult levels, perhaps due to the increased relative size
of the liver and/or higher expression of xenobiotic-metabolizing
enzymes (166)15.
Based on non-fatal poisoning data from the US, child toxin
avoidance and metabolism mechanisms seem to work well: poi-
soning rates are highest in 1–2 year olds and then drop rapidly from
2 to 6, remaining low until adolescence (Figure 4), a pattern that
mirrors the ontogeny of neophobia. Of course, this pattern might
reflect other factors, such as increasingly tight restrictions on access
14Chocolate, a concoction of sugar and fermented cacao beans, sometimes with milk
and other flavors, is an exception as it contains several psychoactive plant xanthine
alkaloids, including theobromine and caffeine. However, the version popular with
children is mostly sugar, fat, and protein.
15Pediatric drug clearance is the subject of continuing theoretical and empirical
investigation, and it is possible that the increased drug clearance in children relative
to adults is an artifact of linear scaling by weight instead of allometric scaling by 3/4
power or body surface area (167). Regardless, children achieve near-adult levels of
drug clearance at an early age.
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Box 1 Bitter taste physiology and genetics.
To understand the strengths and limitations of the evidence for age and sex differences in taste, especially in bitter taste (toxin detection), it
is helpful to know a bit about taste physiology and genetics, and the history of taste research. Taste receptor cells are each tuned to one of
the five basic taste modalities: sweet and umami, which identify sugars and amino acids, respectively, two key nutrients; salty, which helps
ensure proper electrolyte balance; and sour and bitter, which detect toxins. Taste buds, which are distributed across the tongue and palate
epithelium, comprise 50–150 taste receptor cells. Circumvallate papillae are located at the back of the tongue and contain thousands of
taste buds; foliate papillae are located along the back edge of the tongue and contain a dozen to hundreds of taste buds; fungiform papillae
are located in the front two-thirds of the tongue and contain one or a few taste buds (155).
In the early 1930s it was discovered that the ability to taste the bitter compound phenylthiocarbamide (PTC) was inherited in a nearly
Mendelian fashion (156, 157), with PTC taste blindness due to a recessive “non-taster” allele at a single locus having a population fre-
quency of about 50% (158). Thus, about 25% of the population are homozygous for the non-taster allele and are non-tasters, and about
75% possesses at least one copy of the dominant taster allele and are “tasters.” The high frequency of the non-tasting allele implies
balancing selection (e.g., heterozygote advantage), but the selective factor remains unknown.
An enormous body of research has explored variation in ability to taste PTC and a related substance, propylthiouracil (PROP), that has method-
ological advantages over PTC. One important finding is that PROP is intensely bitter for a subset of tasters, termed “supertasters,” and
only mildly bitter for other tasters. Although it is tempting to conclude that supertasters are those who are homozygous for the taster allele,
genotype, number of fungiform papillae (FP), and perhaps other factors make separate contributions to perceived PROP bitterness (159).
In the early 2000s, the genes for bitter, sweet, and umami taste receptors were identified. Whereas only 3 genes are involved in sweet and
umami taste (T1R1, T1R2, and T1R3), about 25 functional genes code for human bitter taste receptors (the T2R family). This makes sense
because the chemical diversity of toxins vastly exceeds that of macronutrients. Some bitter taste receptors respond to as many as 1/3 of
known bitter compounds, whereas others respond to only a few; many bitter compounds active multiple receptors (118).
The gene responsible for the bimodal taste distribution of PTC/PROP was finally identified as one of the bitter taste receptors, T2R38, with
tasters being homozygous or heterozygous for the PAV allele, and non-tasters being homozygous for the AVI allele (158). Thus, although
human bitter taste is mediated by 25 taste receptors – all with allelic variation, all whose phenotypic expression is undoubtedly modified by
other genes and environmental factors, and which, as a group, respond to thousands of compounds – most research on human bitter taste
is based on the taste response to PTC or PROP, which is largely (but not entirely) mediated by two alleles of a single bitter taste receptor
with a distinctive pattern of balancing selection. [Quinine, which activates 9 T2R receptors (118), is another bitter taste stimulant used in
many studies.]
A further complication is that both T2R38 genotype and PROP phenotype predict intensity of non-bitter tastants, such as NaCl (salty),
sucrose (sweet), and citric acid (sour). And even after controlling for T2R38 genotype, number of fungiform papillae, and nonoral sensory
standards, PROP bitterness predicts intensity of other tastants (159). This means, among other things, that inter-individual differences in
the intensity of toxicity signals inferred from T2R genotype or PROP phenotype might also predict differences in the intensity of nutrient
signals, with potentially complex effects on ingestion.
to toxic substances and/or improved training of children with
age. Poisoning rates increase sharply at the onset of adolescence,
paralleling reduced neophobia and the onset of substance use.
The apparent existence of heightened toxin defenses in children
strongly suggests that, for much of human evolution, the costs of
exposure to plant toxins during childhood have been high, but
diminished as brain and other organ development neared com-
pletion, i.e., in adolescence. Although ancestral human children
could not completely avoid plant toxins, we propose that during
childhood the costs of consuming plant substances with high lev-
els of neurotoxins but low levels of macronutrients almost always
outweighed the benefits. The result is that children’s heightened
toxin defense mechanisms usually prevent drug ingestion, which
explains children’s virtually non-existent drug use.
4.2.2. Increases in fitness benefits across development
The hypothesized neurotoxin regulation mechanism functions to
minimize the costs of exposure, and maximize the benefits. In
addition to the evidence that the costs of neurotoxin exposure
were diminishing in adolescence, there is also evidence that the
putative anti-parasite benefits were increasing. In populations with
endemic helminth infections (which presumably include ancestral
human populations), individuals are born without infections but
acquire them as they age. At the same time, they gradually acquire
protective immunity. As a likely result of these two processes, infec-
tion levels peak in middle childhood or adolescence in many pop-
ulations, with the age of the peak dependent on the parasite trans-
mission rate and the rate at which individuals become immune
(a higher transmission rate leads to an earlier, more intense peak)
(169–171). See Figure 5A. This peak could have selected for a
predisposition to initiate drug use at this time to maximize pro-
phylactic or therapeutic benefits. Intriguingly, in populations with
endemic Schistosoma haematobium infection the immune system
itself appears to undergo an age-related antibody switch. Theo-
retical and empirical results suggest this reflects a transition from
an early non-protective response based on exposure to eggs to a
later protective response stimulated by the death of adult worms
(172) (Figure 5B). If the immune system response to a helminth
infection exhibits a switch-like transition in adolescence, then so,
too, might behavioral defenses, such as self-medication.
Attracting mates is another possible benefit for adolescents but
not children. Sexually selected signals, such as peacock tails and
bird songs, are widespread in nature and usually emerge at the
end of the juvenile period to advertise sexual maturity and mate
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quality to the opposite sex (173, 174). Similarly, conspicuous psy-
choactive substance use, which under the hypothesis cannot begin
until the risk of teratogenesis has abated, would be a reliable cue
or signal that a developmental milestone had been achieved, such
as maturation of the nervous system and perhaps gonads or other
organs16. Such a signal might attract mates (175) and other social
partners because a developmentally mature individual would be
able to provide them greater benefits. A reliable cue or signal of
developmental maturity would be especially important in popu-
lations, such as most hunter-gatherers, that do not keep track of
16It would also signal well-functioning detoxification mechanisms, of course.
FIGURE 4 | US unintentional non-fatal poisoning rate vs. age,
2001–2011. There is a dramatic decline in rates during childhood, a dramatic
increase during adolescence, and the female (but not male) rate declines
steadily during women’s reproductive years (about age 18–38). The x-axis is
on a log scale to improve display of the lower age range. Data from Centers
for Disease Control and Prevention (168).
chronological age yet choose mates and social partners based on
qualities that vary with age but are otherwise difficult to discern.
In support of this hypothesis, the age of onset of sexual behav-
ior closely parallels that of drug use (compare Figures 1 and 6).
Smoking initiation is significantly influenced by perceived ben-
efits like looking grown up (176); and in adolescents, perceived
maturity, substance use, sexual behavioral, and prestige are all
correlated (177, 178). Young smokers are also more risk taking
and impulsive, traits that characterize males engaged in intrasex-
ual competition (179–181), and engage in earlier sexual behavior
(182), all of which suggest a link between substance use and mat-
ing. Indeed, higher mating effort is related to more smoking and
more lenient attitudes toward drug use (183, 184). But, smok-
ing has well-documented negative effects on female reproductive
function [reviewed in Ref. (185)], and there is also evidence that it
negatively impacts male reproduction, including erectile function
(186, 187), so the signaling benefits to either sex would need to
outweigh these costs17.
The neurotoxin regulation hypothesis, like the imbalance
hypothesis, involves a cost-benefit analysis by children, but it dif-
fers from the imbalance hypothesis in a number of ways. First, we
hypothesize that neurotoxin regulation involves specialized cir-
cuits and is not based solely on domain-general learning. Second,
although these mechanisms take into account warnings from oth-
ers, they rely heavily on bitter taste receptors and other chemosen-
sors. Third, because the cost of ingesting too much neurotoxin
vastly outweighs the cost of not ingesting enough, the mechanisms
are biased against consumption. Fourth, the circuitry is well-
developed in early childhood, although its functioning changes
across development to reflect changes in the costs and benefits of
neurotoxin exposure.
5. SEX DIFFERENCES IN SUBSTANCE USE
There is a global male bias in substance use among adults, albeit
one that is less dramatic than the age bias, and that varies by nation,
substance, age, birth cohort, and other factors. Male prevalence
of smoking is almost always greater than female prevalence, for
instance (Figure 7). The two exceptions in these data are Nauru (a
small island in the south Pacific) and Sweden. The Swedish data
17It is possible that such costs could increase the credibility of the signal, sensu (188,
189).
FIGURE 5 | (A) Intensity of Schistosoma haematobium infection in two
Zimbabwean populations with high transmission rate (solid line) and low
transmission rate (dashed line). (B) The resulting antibody switch. The y-axis
represents fractions of the two populations with high levels of anti-soluble
egg antigen specific IgG1 relative to IgA (as absorbance at 492 nm).
Reproduced from Ref. (170).
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FIGURE 6 | Age of first sexual intercourse in NHANES data. This
cumulative distribution closely resembles that of age of first substance use
seen in Figure 1. Data from Ref. (123).
FIGURE 7 | Female vs. male smoking prevalence across nations. The
solid diagonal line represents equal prevalence. Values coded as “<1%”
set to 0. Data from the Tobacco Atlas (http://www.tobaccoatlas.org).
are misleading, however, because the use of oral tobacco products
is high among Swedish men but low among Swedish women. Thus,
far more Swedish men use tobacco (40%) than do Swedish women
(23%) (190).
The large cross-national WMHSI study (120) found that the
odds ratio of women initiating use of alcohol, tobacco, cannabis,
and cocaine use in any year of life, vs. men, ranged from 0 for
tobacco use in Nigeria and 0.1 for cocaine use in Mexico and
Columbia (large male biases) to a non-significant 0.8 for cannabis
use in France (no sex bias). Although most of these ratios indi-
cated a statistically significant male bias, when sex differences were
examined by age there was clear evidence that, for some substances
in some populations, they were narrowing in younger cohorts,
especially for the legal drugs alcohol and tobacco, and in sev-
eral cases there were no significant sex differences. In no case,
though, were women significantly more likely to initiate use of
these substances than men.
In contrast to the foregoing substances that either show a clear
male bias, or no bias, there are some drugs that are more likely to be
used by females of certain ages in some populations. For example,
there is historical evidence for a female bias in the use of opioids in
the late 19th and early 20th century US (191). In the US in recent
years, adolescent girls (12–17) were more likely than adolescent
boys to use alcohol and be non-medical users of psychotherapeu-
tic drugs. Nevertheless, in the population as a whole, US men were
more likely than women to be users of all categories of drugs,
including psychotherapeutic drugs and alcohol (192, 193).
As with age bias, evidence of sex bias in substance use is
based primarily on self-report, and could therefore reflect a sex
bias in willingness to admit substance use rather than a sex bias
in substance use itself. A comprehensive review of studies that
compared self-reported smoking status to smoking status deter-
mined by cotinine levels (the biomarker of nicotine exposure)
found that smoking was usually under-reported (194). A sex bias
in under-reporting is less clear, however, with some studies find-
ing that women under-report more than men, others finding that
men under-report more than women, and culture seeming to
play an important role. In two recent US studies, for instance,
women’s self-reports were more accurate than men’s, or even
overestimated cigarette consumption relative to men (195, 196),
whereas in a large Korean study the ratios of cotinine-verified
to self-reported smoking rates were 2.36 for women (substan-
tial under-reporting) and 1.12 for men. Even so, cotinine-verified
smoking rates were much higher in Korean men (50.0%) than
women (13.9%) (197).
In short, unlike the nearly uniform global absence of child
drug use (Figure 1), there is considerable heterogeneity in the
prevalence of adult drug use by sex (e.g., Figure 7). This hetero-
geneity suggests that multiple factors differentially affect women’s
and men’s drug use, perhaps including sex differences in access to
drugs and sex differences in formal and informal social penalties
and rewards for using drugs. At the same time, a greater preva-
lence among women appears to be the exception rather than the
rule (e.g., Figure 7), which suggests that biological sex itself might
play an important role in the decision to use, or not use, drugs.
5.1. THE HIJACK MODEL OF SEX DIFFERENCES IN SUBSTANCE USE
Women enjoy sugar, needless to say, and, in the US at least, eat as
much of it as men (as a fraction of total calories) (198). This implies
that there are no gross differences in food reward that would
explain sex differences in substance use. On the other hand, there
are numerous sex differences in motivation, reinforcement, and
reward, and their underlying neural mechanisms that might. We
will focus on the work of Becker and colleagues, who have written
extensively on sex differences in the neurobiology of motivation
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and reward, and the implications for sex differences in drug use
(199–202).
Becker and colleagues base their model on a plausible evolu-
tionary account of sex differences in motivation rooted in parental
investment theory. Parental investment is any investment, such
as food or protection, by the parent in an individual offspring
that increases the offspring’s survival (and hence reproduction) at
the cost of the parent’s ability to invest in other offspring (203).
Females in most animal species, including those that serve as mod-
els in drug research (e.g., rats, monkeys), invest more in offspring
than males via, e.g., larger gamete size, internal gestation, and var-
ious forms of postnatal care, such as lactation. Male investment in
offspring is minimal. As a consequence, female and male repro-
ductive strategies diverge. Female fitness is largely constrained by
access to the resources necessary to support high levels of parental
investment, whereas male fitness is largely constrained by access
to mates. Males therefore compete with other males for females,
and females are choosey about mates (e.g., mating with males that
exhibit higher genetic quality).
Becker et al. argue that, in rats, sex differences in parental invest-
ment have resulted in the evolution of sex differences in sexual and
parenting motivation,and that some of these differences are shared
with humans (200). In rats, male sexual motivation is constant, in
line with a male strategy to maximize fitness by maximizing the
number of mates. Male sexual motivation (but not mounting)
is mediated by the MDS. Female sexual motivation, in contrast,
depends on context and timing. Female rats are sexually receptive
(estrus) for about 1 day of their 4–5 day estrous cycle. At this time,
females “pace” copulations, and pregnancy is more likely to result
when coital stimulation occurs at a particular rate. This appears
to be a mechanism of female choice because dominant male rats
contribute more intromissions and tend to give each female more
ejaculations than subordinates (204). Female pacing is mediated
by the MDS, and dopamine increases only when females antic-
ipate receiving copulatory stimulation at their preferred rate of
intromission.
There are also pronounced sex differences in parental motiva-
tion. Female rats exhibit a strong motivation to gain access to pups
but males do not. There is some evidence that the MDS is involved
in maternal motivation.
According to Becker et al., these sex differences in rat neurobi-
ology emerge, in part, from the effects of gonadal hormones on
the developing brain, particularly during the perinatal and peripu-
bertal periods18. In addition, sex differences in gonadal hormones
can result in sex differences in adult brain function.
Becker and Taylor [(200), p. 185] postulate that “Once sex
differences in motivational circuits had evolved . . . there were
unforeseen consequences that resulted in many other motiva-
tions systems being sexually dimorphic as well. Nowhere is this
18Becker et al. aim to explain sex differences in drug use, not age differences. But
their theory could explain the dramatic age differences discussed earlier. If drugs
specifically hijacked the mechanisms underlying sexual behavior, parenting, or pair-
bonding, then drug use would only occur when these systems became active, i.e.,
during adolescence. This would seem to imply, however, that drug use would then
be more closely associated with sexual, parenting, or pair-bonding emotions, which
is debatable.
so striking as in drug addiction. Sex differences emerge in all
phases of the addiction process including initiation and prevalence
of use, patterns and levels of use, the progression to addiction,
withdrawal, and relapse.” To more specifically link sex differences
in drug use to sex differences in motivation, Becker and Taylor
[(200), p. 178] argue that “motivation in females is modulated by
gonadal hormones, and the female brain is more vulnerable to be
co-opted by exogenous agents that induce constant activation (e.g.,
drugs of abuse) than are males.” And, “Sex differences in neural
circuitry of attachment may spill over into other motivational sys-
tems too, including non-reproductive motivations for drugs. The
development of strong attachments, and addictions or compulsive
behaviors may occur through activation of the neural system that
mediates maternal motivation; thus, females can become addicted
to drugs more rapidly than males.”
Becker and colleagues cite a wealth of evidence from laboratory
rats and humans that gonadal steroid hormones modulate drug-
related behaviors, and that, by a number of measures, females
in both species are more vulnerable to the effects of drugs (par-
ticularly cocaine). These sex-specific effects include more rapid
progression from initial drug use to dependence in women, and
more rapid acquisition of cocaine self-administration in female
rats; greater stress-induced drug craving in women and female
rats; and greater stress-induced reinstatement of drug use in
women and female rats. Becker et al. (202) argue, further, that
whereas men tend to use drugs for sensation seeking (positive
reinforcement), women tend to use drugs to reduce stress or self-
medicate psychological distress (negative reinforcement). Stressed
or psychologically distressed individuals “enter into the down-
ward spiral [toward addiction] already burdened with neurological
changes that may promote their transition to addiction more
rapidly.”
In summary, in rats the neurobiology of sexual and parental
motivation and reward differs among the sexes and involves sex
differences in the response of the MDS, and Becker et al. argue
that these sex differences underlie sex differences in the animals’
responses to drugs of abuse. Many sex differences in human drug
use are rooted in sex differences in human neurobiology that
resemble those seen in rats. The upshot of most sex differences
is that females are more vulnerable to the co-opting effects of
drugs than males.
Becker and colleagues’ conclusion would seem to predict that
the prevalence of drug use would be higher in women. Instead, for
most drugs in most populations, the prevalence is higher, often
much higher, in men (e.g., Figure 7). Becker et al. acknowledge
higher male prevalence, and contend that it is a consequence of
historical, cultural, and social factors. But the Becker et al. model
is almost exclusively one of neurobiological sex differences and
only briefly sketches what those historical and sociocultural factors
might be: “Overall, availability of drugs coupled with dissatisfying
social conditions, stress, anxiety, and depression tends to exacer-
bate drug abuse and addiction in women. While such conditions
can also increase drug use in men, it is our hypothesis that on
the average this happens more often in women” [Ref. (202), p.
5]. Maybe so, but of these factors, only “availability of drugs” has
a plausible male bias that might explain the pervasive male bias
in the prevalence of drug use. Like the imbalance model of drug
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use in children, then, the Becker et al. model puts the onus for
lower prevalence in women on their socially restricted access to
drugs.
5.2. THE NEUROTOXIN REGULATION MODEL OF SEX DIFFERENCES IN
DRUG USE
The neurotoxin regulation model of sex differences, like the Becker
et al. model, is grounded in evolved sex differences in parental
investment (and thus applies to adults, not children). According
to the neurotoxin regulation model, the decision to ingest plant
neurotoxins reflects an evolved calculus that weighs fitness benefits
against costs. Because we take an evolutionary perspective, we con-
sider the fitness benefits and costs of neurotoxin intake to ancestral
men and women. Most of the fitness benefits and costs of regu-
lated neurotoxin intake would probably have been similar for men
and women, but women of childbearing age faced an additional
cost: potential disruption of fetal and infant development.
Ancestral women had no access to highly reliable modern
contraceptive technologies. Across contemporary hunter-gatherer
societies that also lack such technologies, the median age at first
birth is 19.25, the median weaning age is 2.5 years, the median
interbirth interval is 3.2 years, and the median total fertility rate is
5.5 (205). Thus, for much of her late teens to her late thirties the
median hunter-gatherer woman is pregnant or lactating.
Ancestral women’s plant ingestion therefore had a profound
impact on the exposure of their fetuses and infants to plant toxins.
Throughout gestation, for instance, maternal serum or urine coti-
nine levels correlate strongly with concentrations in fetal tissues
and fluids such as cord blood, umbilical cord tissue, meconium,
amniotic fluid, and placenta [Ref. (206), and references therein].
In infants breastfed by smoking mothers, cotinine concentrations
in the urine are in the range of adult smokers (207). Fetal exposure
to nicotine and other tobacco teratogens is associated with reduced
academic achievement and intellectual abilities later in life (208).
Among contemporary hunter-gatherers, a median 21% of chil-
dren die within the first year of life, and 45% within the first
15 years of life, rates similar to those seen in chimpanzees (205),
which implies intense selection to protect offspring from harm.
We therefore propose that, to maximize the fitness benefits from
their high investment in offspring, women evolved to be more
averse to toxins in their reproductive years, and to metabolize
and eliminate them more rapidly. The tradeoffs of increased toxin
defense included dietary restrictions and thus either reduced nutri-
ent intake or increased search and processing times, and energy
allocation to toxin metabolism at the expense of, e.g., activity levels
and immunity.
Contemporary hunter-gatherer societies are characterized by
a sexual division of labor, with men typically hunting or fishing,
women typically gathering plant foods, and food widely shared
among all group members (there is considerable variability, how-
ever, and women often hunt and men often gather) (205). If
ancestral human societies were also characterized by a similar sex-
ual division of labor involving foraging of plant vs. animal foods,
then this could have been an additional factor for the evolution of
sex differences in chemosensing and toxin defense.
Drugs of abuse activate most toxin defense mechanisms,
including those governing intake such as bitter taste receptors and
conditioned taste avoidance, and higher bitter sensitivity seems to
reduce drug intake. For instance, T2R38 genotype predicts drug
use in adults, with tasters consuming less than non-tasters. Ethanol
tastes bitter, and beer and wine both contain additional bitter com-
pounds (209–211). Alcohol intake is lowest in PAV homozygotes
PAV/AVI heterozygotes (tasters); in one study (212) it was almost
half that reported by AVI homozygotes (non-tasters) [reviewed
in Ref. (213)]. A number of studies suggest that high bitter taste
sensitivity in adults is also protective against nicotine dependence
(214–219), albeit with some inconsistencies [e.g., Ref. (216)].
We therefore propose that heightened toxin defense in women
(evidence for which we discuss next) results in their lower preva-
lence of drug use. We also propose that learning plays a key role:
the effects of plant toxins on fetal and infant development are not
completely predictable from their immediate physiological effects
(e.g., bitter taste, nausea), so women should be attentive to infor-
mation from others regarding the negative effects on offspring
(or lack thereof) of ingesting particular plants, and adjust intake
accordingly.
There is considerable evidence for sex differences in toxin dis-
position. Less clear is whether these differences are a consequences
of greater toxin defense in women, particularly pregnant or lac-
tating women, or instead are byproducts of, e.g., sex differences
in physiology, such as body size and composition. Women have a
higher percentage of body fat than men, for example,and lipophilic
drugs, such as THC, are sequestered in fat tissue, which might
account for some sex differences in response to THC (220). Sex
differences in toxin disposition could even be due to sex differences
in exogenous factors like diet. To give one example, grapefruit juice
inhibits CYP3A4, an important drug metabolizing enzyme (221).
If there were a sex difference in consumption of grapefruit juice,
this could result in sex differences in the disposition of many drugs
and toxins.
We will briefly review evidence that seems to suggest enhanced
toxin defenses in women, while acknowledging considerable
uncertainty in the interpretation of this evidence, that much evi-
dence suggests no sex differences, and that some evidence points
in the opposite direction. The challenge in resolving the nature
of sex differences in toxin defense mechanisms is exacerbated by
a lack of data on drug disposition in women, as pharmaceuti-
cal research often excluded women, particularly pregnant women,
from clinical trials over concerns of possible drug teratogenicity.
We divide women’s lives into 3 distinct reproductive phases: a
sexually active but pre-reproductive phase that starts in early-to-
mid adolescence and ends at the age of first pregnancy; a reproduc-
tive phase involving alternating periods of pregnancy and lacta-
tion; and a post-reproductive phase that begins with menopause.
We propose maximum sex differences in toxin defense during the
reproductive phase, especially during pregnancy and lactation, and
consequently maximum sex differences in the prevalence of sub-
stance use, but reduced sex differences in toxin defense in the
pre- and post-reproductive phases, and consequently reduced sex
differences in the prevalence of substance use.
Modern birth control technologies complicate interpretation of
sex differences in drug use patterns and toxin defense mechanisms
because for the first time in our evolutionary history women can
indefinitely extend their sexually active pre-reproductive phase;
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reliably alternate psychoactive drug use with pregnancy and lac-
tation; minimize breastfeeding by rapidly transitioning to infant
formula; and sharply limit total fertility. In other words, dur-
ing their reproductive years most modern women can, if they
choose, use psychoactive drugs much of the time with little risk of
fetal or infant exposure. Hormonal birth control introduces a fur-
ther complication in that steroid hormones modulate xenobiotic
metabolism (see below), and might also alter psychobehavioral
toxin defense mechanisms.
5.2.1. Heightened toxin detection in women
Women have more fungiform papillae and more taste buds than
men and, according to most studies, are able to detect lower con-
centrations of PROP and are more likely to be supertasters (222).
High bitter sensitivity, in turn, generally predicts reduced veg-
etable intake in both women and men [e.g., Ref. (223); for review,
see Ref. (224)]. The major caveat is that research on bitter taste
has been dominated by investigation of two compounds, PTC
and PROP, which primarily activate a single bitter taste receptor,
T2R38 (see Box 1); it is unknown whether sex differences in bitter
taste sensitivity extend to a broad range of ecologically important
substances and all bitter taste receptors.
5.2.2. Heightened drug metabolism in women
Nicotine metabolism is accelerated in women (225). Nicotine
and most other drugs are metabolized by liver cytochrome P450
enzymes. About a dozen of the 57 human P450 enzymes are pri-
marily responsible for xenobiotic metabolism. Of the many factors
influencing sex differences in drug disposition, there is widespread
agreement that sex differences in hepatic enzyme activity play a
major role.
The CYP3A family is the most abundant P450 in the liver,
and is responsible for the metabolism of >50% of all commer-
cial drugs. Most studies have found that women have about
20–30% higher CYP3A-mediated clearance, albeit with consid-
erable variation across drugs and individuals (226, 227). Nuclear
receptors (NR) are transcription factors that are activated by small
lipophilic molecules, including plant toxins; NR, in turn, regu-
late the expression of many genes, including P450 enzymes. In
rodents, sex differences in NR-regulated liver metabolism raise the
possibility that the female liver is more efficient in neutralizing
substances (228). In a study of 374 drug metabolizing and trans-
porter genes in human liver tissue, sex differences in expression
were found in 77 (21%). Of these, 58 (75%) had higher expression
in women (229).
Other evidence suggests few sex differences in metabolism,
or, for some substances, even a male bias. For instance, other
than CYP3A, sex differences in the activities of most xenobiotic-
metabolizing P450s are unresolved (227, 230). Some substrates of
CYP1A2 and CYP2E1, which metabolize 4 and 2% of known com-
mercial drugs, respectively (231), are more rapidly metabolized in
men (232), and men appear to have greater hepatic expression of
p-glycoprotein, an important drug transporter (230).
Based on FDA data, women suffer more prescription drug-
related adverse events, and these events are of a more serious
nature. This might indicate that women are more vulnerable to
toxins, not less. It could also reflect the fact that most drug tri-
als have involved men, and thus dosages are inappropriate for
women due to smaller body size, differences in body composition,
sex differences in pharmacokinetics, sex differences in pharmaco-
dynamics (the effects of the drug), biased reporting, or perhaps
that women more often use multiple drugs, increasing the risk
of an adverse event (230). Because xenobiotics can both induce
and inhibit P450 expression, sex differences in diet could also
contribute to sex differences in adverse events.
In contrast to the FDA data on adverse events for prescription
drugs, US non-fatal poisoning rates indicate that although there
is no sex difference in adolescence, women have a markedly lower
rate than men from age 20–75 (Figure 4). It is not clear whether
this reflects heightened toxin defenses in women (including avoid-
ance), or one or more of the many other factors influencing toxin
ingestion, metabolism, physiological effects, and elimination.
5.2.3. Pregnancy
During pregnancy, women have to meet increasing demands for
macro and micronutrients while at the same time protecting their
fetuses from plant teratogens, which exist in higher concentra-
tions in the wild foods consumed by ancestral women than in
the domesticated grains, vegetables, and fruits consumed by most
women today. In addition, to accommodate a fetus expressing
paternal genes, as well as changes in vulnerabilities to infection,
there are substantial changes in maternal immunity.
Studies based on PTC/PROP find that bitter taste reaches a
maximum in the first trimester of pregnancy, which would make
women particular good “poison detectors” to protect the fetus
from teratogens (233). A study using caffeine, however, which
activates different T2Rs, found reduced bitter taste sensitivity in
pregnant women vs. non-pregnant controls, an effect the authors
interpret as functioning to increase variation in diet in order to
increase weight during pregnancy (234).
Approximately 50–90% of pregnancies involve heightened food
aversions, and up to 80% involve nausea and vomiting. This is
puzzling given the increased micro- and macro-nutrient require-
ments of pregnancy. Yet nausea and vomiting in pregnancy (NVP),
which tends to occur in the first trimester, is associated with
positive pregnancy outcomes. Two complimentary adaptationist
accounts of NVP have garnered widespread attention. One high-
lights aversions to meat, because meat is likely to harbor pathogens,
and women are immunosuppressed in their first trimester (235,
236). The other, supporting the view we advance here, highlights
aversions to toxic plants because these pose a risk to the develop-
ing fetus, especially during organogenesis (237, 238); for review,
see (239). The two hypotheses broadly overlap, however, because
microbial food-borne pathogens produce some of the most toxic
substances known to science. Botulinum toxin, for instance (a
cholinergic toxin like nicotine) has a lethal dose on the order of
nanograms per kilogram of body mass (240).
Pregnancy-related aversions include drugs like alcohol, cof-
fee, and tobacco (239, 241), and these aversions appear to reduce
drug intake. Women smokers, for example, often reduce or cease
smoking during pregnancy, and one important reason seems to be
sensory aversions to tobacco smoke (242).
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There are also pregnancy-related increases in drug metabo-
lism. Nicotine metabolism, for instance, is accelerated in preg-
nancy (243). Activities of CYP3A4, CYP2C9, and CYP2D6,
which together are responsible for the metabolism of >80% of
commercial drugs, are increased several-fold during pregnancy.
There is also evidence for increased activity of the phase II
enzyme UGT1A4, as well as the drug transporters p-glycoprotein,
OATP1B1, and OCT2. However, CYP1A2, which is responsible
for the metabolism of about 4% of commercial drugs, is down-
regulated. Pregnancy-related changes in activities of other P450
enzymes are equivocal, with some evidence for increased activity
of CYP2B6.
Pregnancy hormones are obvious potential modulators of
P450 enzymes. An in vitro study found that pregnancy-levels
of estradiol enhanced CYP2A6, CYP2B6, and CYP3A4 expres-
sion, whereas progesterone induced CYP2A6 (minor), CYP2B6,
CYP2C8, CYP3A4, and CYP3A5 expression (244). For reviews of
drug disposition in pregnancy, see (231, 245–247).
5.2.4. Menopause
If female toxin defenses are heightened to protect their fetuses
and nursing infants, and if heightened defenses involve tradeoffs
against other important functions and behaviors, then defenses
should decrease to male levels post menopause. Consistent with
this view, perceived bitterness of PROP remains relatively con-
stant for women in their childbearing years, and then declines
after menopause, whereas for men it shows a more gradual and
steady decline from their 30s onward (233). Nicotine metabo-
lism is accelerated in younger women compared to men, but is
no different in menopausal and postmenopausal women than
men (225). Data on the relationship between menopause and
clearance of other drugs is conflicting, however. For example,
some substrates of CYP3A4 are cleared less rapidly in menopausal
and postmenopausal women, consistent with the hypothesis, but
others show no difference (230).
5.2.5. Summary of sex differences
In summary, there is enough evidence to propose (but not to con-
clude) that toxin defenses are heightened in women during their
childbearing years; that the enhancement serves, at least in part,
to protect the fetus and infant; that it reduces intake of drugs; and
that it is partially responsible for the lower prevalence of drug use
of women in their 20s and 30s. We speculate that the diminishing
sex differences in use of some substances in younger cohorts might
partially reflect the global fertility transition over the last several
decades that involves increased use of birth control, later age at
marriage, delay of first birth, and lower total fertility (248), all of
which would allow women, especially younger women, to increase
drug intake while limiting fetal and infant exposure. If the fertil-
ity transition is partly a consequence of reduced child mortality
rates combined with women’s increasing economic importance in
society and their need for increased education, and thus a reduced
emphasis on their reproductive roles, this might also have reduced
social disapproval of drug use in women relative to men, further
increasing women’s access to, and willingness to use, drugs.
Finally, we suggest that, for the human data at least, the Becker
et al. and neurotoxin regulation models are complimentary rather
than contradictory. Whereas the neurotoxin regulation model of
sex differences emphasizes female avoidance and elimination of
plant toxins, the Becker et al. model primarily applies to women
who have already chosen to use drugs, and who therefore differ
from the general female population; given lower female preva-
lence of drug use, they might differ more than male drug users
differ from the general male population. In addition, as Becker
et al. emphasize, men and women often use drugs for different
reasons, with women more often using drugs to alleviate stress or
depression and men more often as a type of risk taking. It is not
so surprising that people who use drugs for very different reasons
would also exhibit important differences in many other facets of
drug use.
6. CONCLUDING REMARKS
We have taken the idea that drugs hijack the brain and reframed it
as a testable hypothesis. We then developed a testable alternative,
the neurotoxin regulation hypothesis. In our view, the dramatic
age and sex differences in drug use are better explained by age
and sex differences in the costs vs. benefits of toxin exposure than
by age and sex differences in reward, supporting the neurotoxin
regulation hypothesis. The case is far from closed, however, and
there is little reason to accept either hypothesis without consider-
able further research. The hijack hypothesis would be supported
by finding that the child MDS generates a pro-drug motivation
that is overridden by deliberations in the prefrontal cortex, per-
haps in response to adult warnings, and/or is thwarted by socially
restricted access to drugs. It would also be supported by finding
that the sex differences in substance use are largely due to sex dif-
ferences in social restrictions on drug use that are independent
of childbearing, and not due to sex differences in a preference to
consume drugs.
The neurotoxin regulation hypothesis would be supported by
finding, instead, that child drug use is rare regardless of adult
warnings or restrictions, there is no pro-drug use signal from the
MDS to override, children are strongly averse to drugs, and, at
least in ancestral populations, there were fitness benefits to drug
use, which first exceeded the costs in adolescence. It would also be
supported by finding that sex differences in drug use are partly a
consequence of maternal toxin defense mechanisms that function
to protect the fetus and infant. Increased drug use by pre- and
post-reproductive women is not surprising, and recent diminish-
ing of sex differences for some drugs in some populations might
be linked to the fertility transition. Product engineering aimed at
increasing women’s drug use, which includes adding sugar and fla-
vorings to alcoholic beverages and cigarettes (249, 250), probably
also plays a role in reducing sex differences.
Tobacco use and abuse of alcohol and other drugs are major
contributors to global disease burden (251, 252). Many pharma-
cological treatments for drug abuse aim to reduce reward (253).
Research on the treatment of substance abuse might benefit by also
investigating pharmacological manipulation and enhancement of
toxin defense mechanisms19.
19Disulfiram is a partial example. It inhibits acetaldehyde dehydrogenase, which, in
individuals who drink, leads to high levels of acetaldehyde,a toxic alcohol metabolite.
The resulting unpleasant reaction deters drinking.
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